Ocugen Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.415
- Today's High:
- $0.4369
- Open Price:
- $0.42
- 52W Low:
- $0.397
- 52W High:
- $2.36
- Prev. Close:
- $0.42
- Volume:
- 989958
Company Statistics
- Market Cap.:
- $110.29 million
- Book Value:
- 0.274
- Revenue TTM:
- $-380
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $-49757000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -51.27%
- Return on Equity TTM:
- -90.34%
Company Profile
Ocugen Inc had its IPO on 2014-12-03 under the ticker symbol OCGN.
The company operates in the Healthcare sector and Biotechnology industry. Ocugen Inc has a staff strength of 84 employees.
Stock update
Shares of Ocugen Inc opened at $0.42 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.42 - $0.44, and closed at $0.42.
This is a 0% increase from the previous day's closing price.
A total volume of 989,958 shares were traded at the close of the day’s session.
In the last one week, shares of Ocugen Inc have slipped by -2.33%.
Ocugen Inc's Key Ratios
Ocugen Inc has a market cap of $110.29 million, indicating a price to book ratio of 3.6519 and a price to sales ratio of 25069.316.
In the last 12-months Ocugen Inc’s revenue was $-380 with a gross profit of $-49757000 and an EBITDA of $-89191000. The EBITDA ratio measures Ocugen Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Ocugen Inc’s operating margin was 0% while its return on assets stood at -51.27% with a return of equity of -90.34%.
In Q2, Ocugen Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Ocugen Inc’s PE and PEG Ratio
- Forward PE
- 15.2207
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.35 per share while it has a forward price to earnings multiple of 15.2207 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Ocugen Inc’s profitability.
Ocugen Inc stock is trading at a EV to sales ratio of 35591.278 and a EV to EBITDA ratio of -3.3624. Its price to sales ratio in the trailing 12-months stood at 25069.316.
Ocugen Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $88.98 million
- Total Liabilities
- $13.46 million
- Operating Cash Flow
- $5.72 million
- Capital Expenditure
- $2.78 million
- Dividend Payout Ratio
- 0%
Ocugen Inc ended 2024 with $88.98 million in total assets and $0 in total liabilities. Its intangible assets were valued at $88.98 million while shareholder equity stood at $70.28 million.
Ocugen Inc ended 2024 with $0 in deferred long-term liabilities, $13.46 million in other current liabilities, 2566000.00 in common stock, $-252441000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $70.58 million and cash and short-term investments were $70.58 million. The company’s total short-term debt was $1,792,000 while long-term debt stood at $1.47 million.
Ocugen Inc’s total current assets stands at $73.45 million while long-term investments were $0 and short-term investments were $0.00. Its net receivables were $0 compared to accounts payable of $3.88 million and inventory worth $0.
In 2024, Ocugen Inc's operating cash flow was $5.72 million while its capital expenditure stood at $2.78 million.
Comparatively, Ocugen Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.42
- 52-Week High
- $2.36
- 52-Week Low
- $0.397
- Analyst Target Price
- $4.58
Ocugen Inc stock is currently trading at $0.42 per share. It touched a 52-week high of $2.36 and a 52-week low of $2.36. Analysts tracking the stock have a 12-month average target price of $4.58.
Its 50-day moving average was $0.52 and 200-day moving average was $0.85 The short ratio stood at 5.78 indicating a short percent outstanding of 0%.
Around 151.3% of the company’s stock are held by insiders while 2420.8% are held by institutions.
Frequently Asked Questions About Ocugen Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. It has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.